TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds

• ClinicalTrials.gov Identifier: NCT02195427
• Recruitment Status: Completed
• First Posted: July 21, 2014
• Results First Posted: March 26, 2018
• Last Update Posted: April 25, 2018
• Sponsor: Teoxane SA
• Collaborator: ethica Clinical Research Inc.
• Information provided by (Responsible Party): Teoxane SA

Study Description

Brief Summary:

The purpose of this study is 1) to compare the effectiveness and safety of TEOSYAL® RHA Global Action versus Juvéderm® Ultra XC, and 2) to compare the effectiveness and safety of TEOSYAL® RHA Deep Lines versus Juvéderm® Ultra XC, in the treatment of moderate to severe nasolabial folds.

Condition or disease	Intervention/treatment	Phase
Nasolabial Folds, Wrinkles	Device: TEOSYAL® RHA Global Action; Device: TEOSYAL® RHA Deep Lines	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 148 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Controlled, Randomized, Double-Blinded, Within-Subject, Multicenter, Prospective Clinical Study of TEOSYAL® RHA Global Action and TEOSYAL® RHA Deep Lines Versus Juvéderm® Ultra XC in the Treatment of Moderate to Severe Nasolabial Folds
• Study Start Date: June 2014
• Actual Primary Completion Date: March 2015
• Actual Study Completion Date: March 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: TEOSYAL RHA Global Action/Juvederm Ultra XC; Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).	Device: TEOSYAL® RHA Global Action; A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2" disposable sterile needles.
Experimental: TEOSYAL RHA Deep Lines/Juvederm Ultra XC; Split-face injection of TEOSYAL® RHA Deep Lines into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).	Device: TEOSYAL® RHA Deep Lines; A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2" disposable sterile needles.

Outcome Measures

Primary Outcome Measures :

1. Non-inferiority of the Delta of TEOSYAL® RHA GA and TEOSYAL® RHA DL Versus Juvéderm® Ultra XC for the Correction of Moderate to Severe NLFs Based on the Wrinkle Severity Rating Scale (WSRS) Score Assessed by the Blinded Live Evaluator (BLE). [ Time Frame: Baseline and 24 weeks after last treatment ]
   TEOSYAL® RHA GA = TEOSYAL® RHA Global Action TEOSYAL® RHA DL = TEOSYAL® RHA Deep Lines WSRS (Wrinkle Severity Rating Scale) is a validated 5-point scale assessing wrinkle severity with 1 being 'absent' and 5 being 'extreme' BLE = Blinded Live Evaluator

Secondary Outcome Measures :

1. Post Injection Treatment Responses (From Common Treatment Responses (CTR) Diary) for Safety Evaluation of TEOSYAL® RHA Global Action (GA) and TEOSYAL® RHA Deep Lines (DL) Versus Juvéderm® Ultra XC (J). [ Time Frame: During 14 days after initial treatment (D0) and touch-up (2 weeks) ]

   The subjects received a diary booklet and instructions for recording his/her observations of the Common Treatment Responses of the study treatments for the first 14 days after each treatment (initial, touch-up). The diary was discussed during each telephone follow-up visit. Subjects should complete the diary at approximately the same time each day (i.e., am or pm).

   The subject diary captured the following Common Treatment Responses (CTR) that occur following the injection of a dermal filler; specifically, redness, pain, tenderness, firmness, swelling, lumps/bumps, bruising, itching, discoloration, and "other".

   The 14-day patient CTR diary included a detailed glossary describing all signs/symptoms listed in the diary; an option was provided to rate "other" if the subject experienced a sign/symptom that is not listed.

   The table presents the number of subjects experiencing at least 1 Common Treatment Response (CTR)

2. Assessment of Injection Site Pain (Visual Analog Scale) of TEOSYAL® RHA Global Action (GA) and TEOSYAL® RHA Deep Lines (DL) Versus Juvéderm® Ultra XC (J). [ Time Frame: During Injection and 5, 15, 30 minutes post-injection ]
   VAS is a 100 mm Visual Analog Scale with 0 meaning no pain and 100 meaning intolerable pain
3. Delta of the WSRS Score Between W24,36,52 and Baseline for TEOSYAL® RHA GA Versus Juvéderm® Ultra XC and TEOSYAL® RHA DL Versus Juvéderm® Ultra XC for the Correction of Moderate to Severe NLFs Based on the WSRS Score Assessed by the BLE [ Time Frame: Baseline and Weeks 24, 36, 52, 64 ]
   TEOSYAL® RHA GA = TEOSYAL® RHA Global Action TEOSYAL® RHA DL = TEOSYAL® RHA Deep Lines WSRS (Wrinkle Severity Rating Scale) is a validated 5-point scale assessing wrinkle severity with 1 being 'absent' and 5 being 'extreme' BLE = Blinded Live Evaluator
4. Delta of the WSRS Score Between W2,4,12,24,36,52,64 and Baseline for TEOSYAL® RHA GA Versus Juvéderm® Ultra XC and TEOSYAL® RHA Deep Lines Versus Juvéderm® Ultra XC for the Correction of Moderate to Severe NLFs Based on the WSRS Score Assessed by the TI [ Time Frame: Baseline and Weeks 2, 4, 12, 24, 36, 52, 64 ]
   TEOSYAL® RHA GA = TEOSYAL® RHA Global Action TEOSYAL® RHA DL = TEOSYAL® RHA Deep Lines WSRS (Wrinkle Severity Rating Scale) is a validated 5-point scale assessing wrinkle severity with 1 being 'absent' and 5 being 'extreme' TI = Treating Investigator
5. Percentage of Responders Based on the Intra-individual Improvement of at Least One Grade in the WSRS Compared to Baseline Assessed by the BLE [ Time Frame: Baseline and Weeks 24, 36, 52, 64 ]
   A responder correspond to a subject with an intra-individual improvement of at least one grade in the WSRS compared to baseline
6. Percentage of Responders Based on the Intra-individual Improvement of at Least One Grade in the WSRS Compared to Baseline Assessed by the TI [ Time Frame: Baseline and Weeks 2, 4, 12, 24, 36, 52, 64 ]
   A responder correspond to a subject with an intra-individual improvement of at least one grade in the WSRS compared to baseline
7. Number of Subjects Scored Either "Much Improved" or "Improved" on Global Aesthetic Improvement (GAI) Scale by the Blinded Live Evaluator (BLE). [ Time Frame: Weeks 24, 36, 52, 64 ]

   Global Aesthetic Improvement (GAI) is a subjective 5-grade scale comprised of "much improved, improved, no change, worse, and much worse" that evaluate the aesthetic improvement from baseline.

   GAI was assessed using the baseline photograph. Each side of the face was assessed independently.

8. Number of Global Aesthetic Improvement (GAI) Responders (i.e., Scoring Either "Much Improved" or "Improved") on GAI Scale. [ Time Frame: Weeks 4, 12, 24, 36, 52, 64 ]

   Global Aesthetic Improvement (GAI) is a subjective 5-grade scale comprised of "much improved, improved, no change, worse, and much worse" that evaluate the aesthetic improvement from baseline.

   GAI was assessed using the baseline photograph. Subjects will be instructed: "Use a mirror to compare your face to the photograph provided to you and rate the degree of aesthetic improvement by using the following scale".

   Each side of the face was assessed independently.

9. Subject's Perception of Treatment Effectiveness as Per the FACE-Q (NLF Domain) Questionnaire [ Time Frame: Immediately post-injection, and weeks 2, 4, 12, 24, 36, 52, 64 ]

   The FACE-Q measures the experience and outcomes of aesthetic facial procedures from the patient's perspective.

   FACE-Q questionnaire is composed of 5 questions with a score linked to answers (1 being 'Not at all' and 4 being 'Extremely').

   The subject was instructed as follows: "These questions ask about how you look right now. With your nasolabial folds in mind (the deep lines that run downward from the sides of your nose), in the past week, how much have you been bothered by:", and provided response.

   • How deep your nasolabial fold are?
   • How your nasolabial folds look when your face is relaxed (still)?
   • How old your nasolabial folds make you look?
   • How your nasolabial folds look when you smile?
   • How your nasolabial folds look compared with other people your age? To calculate the FACE-Q, outcomes from all 5 questions were pooled and adapted to a scale to 100 units. Data were also transformed so that higher scores reflected a beneficial outcome.
10. Subject's Satisfaction Score [ Time Frame: Weeks 2, 4, 12, 24, 36, 52, 64 ]
    Subjective 5-point scale with 1 being 'very satisfied' and 5 being 'very dissatisfied'
11. Volume to Obtain Optimal Cosmetic Result (Initial Treatment + Touch-up) [ Time Frame: Week 2 ]
12. Number of Subjects Receiving Touch-up Treatment. [ Time Frame: Week 2 ]
13. Number of Subjects Receiving Re-treatment [ Time Frame: Weeks 24, 36, 52, 64 ]

Eligibility Criteria

• Ages Eligible for Study: 22 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Outpatient, male or female of any race, 22 years of age or older; female subjects of childbearing potential must have a negative urine pregnancy test and practice a reliable method of contraception
• NLFs classified as WSRS grade 3 or 4 (same score for each side)
• Willing to abstain from facial aesthetic procedures/therapies that could interfere with study evaluations
• Able to follow study instructions and likely to complete all required visits;
• Signed informed consent and HIPAA (Health Insurance Portability and Accountability Act) form

Exclusion Criteria:

• Female subjects that are pregnant or breast-feeding, or of childbearing potential and not practicing reliable birth control
• Known hypersensitivity/allergy to any component of the study devices
• Known sensitivity to local anesthetics of the amide type, history of multiple severe allergies, history of anaphylactic shock
• Known susceptibility to keloid formation, hypertrophic scarring or clinically significant skin pigmentation disorders
• Clinically significant active skin disease within 6 months
• History of active chronic debilitating systemic disease
• History of connective tissue disease
• History of malignancy (excl. non-melanoma skin cancer) within past 5 years
• History of bleeding disorders
• Need for clinically significant and continuous medical treatment within 2 weeks prior to first visit
• Received/used a prohibited treatment/procedure within certain time periods (e.g., bioresorbable fillers, NSAIDS, acetylsalicylic acid, high dose vitamin E, corticosteroids, interferon, anti-coagulation therapies, laser/light therapies, botulinum toxin injections (frontalis and glabella complex treatment permitted), prescription strength topical retinoids, facial peels, excisional facial surgery, clinically significant oral or maxillofacial surgery)
• Clinically significant alcohol or drug abuse, or history of poor cooperation, non-compliance with medical treatment, or unreliability
• Exhibit a physical attribute(s) that may prevent assessment or treatment of NLFs such as excessive facial hair, traumatic or surgical facial scars, and/or excessive hyperpigmentation in the treatment areas
• A condition or situation that may put the subject at significant risk, confound the study results, or significantly interfere with the subject participation

Contacts and Locations

Locations

United States, Alabama

United States, Alabama

Birmingham, Alabama, United States

United States, California

United States, California

Beverly Hills, California, United States

United States, Santa Monica

Santa Monica, California, United States

United States, Florida

United States, Florida

Coral Gables, Florida, United States

United States, Massachusetts

United States, Massachusetts

Chestnut Hill, Massachusetts, United States

Sponsors and Collaborators

Teoxane SA

ethica Clinical Research Inc.

More Information

• Responsible Party: Teoxane SA
• ClinicalTrials.gov Identifier: NCT02195427
• Other Study ID Numbers: TEO-RHA-1302
• First Posted: July 21, 2014
• Results First Posted: March 26, 2018
• Last Update Posted: April 25, 2018
• Last Verified: March 2018

Keywords provided by Teoxane SA:

Nasolabial folds; Dermal filler; Hyaluronic acid (HA); Wrinkles